NCT07882173

Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi)

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2026-10-29Est. Completion: 2030-11-01

Enrollment target: 24 participants

Locations

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Contact

Lymphoid Malignancies Team Study Coordinnhlbidi-rocdlmtrn@nih.gov (301) 827-1203

Lymphoplasmacytic LymphomaWaldenstrom Macroglobulinemia

This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrut…

Tucson, United StatesEst. completion Mar 31, 2028

Waldenstrom MacroglobulinemiaLymphoplasmacytic LymphomaMonoclonal B-Cell LymphocytosisSmall Lymphocytic LymphomaCLL (Chronic Lymphocytic Leukemia)

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.